Target intelligence / Profile preview

T cell receptor delta joining 4 (TRDJ4)

Target
TRDJ4
Molecular classification
Other (immunogenetic gene segment), Not a full receptor, not an enzyme, not a transporter
01

Overview

T cell receptor delta joining 4 (TRDJ4) is a *joining (J) gene segment* of the T cell receptor delta (TRD) locus in humans. It encodes a short stretch of amino acids that, through V(D)J recombination, contributes to the hypervariable region (CDR3) of the T cell receptor delta chain. This region is essential for antigen recognition diversity by γδ T cells. TRDJ4 itself is not transcribed or translated as a stand-alone product; it forms part of the mature TCR delta chain only following rearrangement with variable (V) and diversity (D) segments during T-cell development in the thymus[1][3][5]. As a small recombination segment, it is not considered a drug target or disease gene, but is crucial for generating the antigen receptor repertoire required for immune recognition. If you are interested in T cell receptor delta (TRD) chain as a potential therapeutic target, the correct entity would be "T cell receptor delta chain" or "T cell receptor (gamma/delta)" rather than an individual joining segment like TRDJ4.

Other names
T cell receptor delta joining segment 4TRDJ4 (self-abbreviation and locus name)
02

Biological functions

Other (codes for a joining segment participating in T cell receptor delta (TRD) chain V(D)J recombination during T cell development)
03

Disease associations

Other (no direct disease association; however, the diversity generated through such segments is critical for immune responses and may be indirectly relevant to immune disorders and cancer, but TRDJ4 itself is not directly implicated as a disease gene)

Beyond the preview

Go deeper on T cell receptor delta joining 4 (TRDJ4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor delta joining 4 (TRDJ4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call